Stocks - Q : Quality | V : Valuation | PT : Price Trend
Funds - P : Performance | Q : Quality
Funds - P : Performance | Q : Quality
BSE: 506128 | NSE: | Pharmaceuticals & Drugs | Small Cap
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation Index Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -1.1% | -1.1% | 1.4% | -5.4% | 2.9% | 5% | -2.6% | 7.8% | 8.9% | 12.5% | - |
| Value Creation Index ⓘ | -1.1 | -1.1 | -0.9 | -1.4 | -0.8 | -0.6 | -1.2 | -0.4 | -0.4 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 15.9 | 7.2 | 5.3 | 5.8 | 6.5 | 7.7 | 2.4 | 7.2 | 7.5 | 7.4 | 8 |
| Sales YoY Gr. | - | -54.4% | -27% | 9.9% | 11.9% | 18.3% | -69.1% | 201.7% | 4.5% | -0.4% | - |
| Adj EPS ⓘ | -1.7 | -1.3 | -0.8 | -1.7 | -1 | -2.4 | -1.3 | 0.5 | 0.9 | 1.5 | 1.4 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | 89.8% | 62.4% | - |
| BVPS (₹) ⓘ | 14.8 | 13.7 | 12.9 | 10.2 | 9.2 | 6.9 | 5.5 | 11.1 | 16.9 | 18.4 | 19.7 |
| Adj Net Profit ⓘ | -1.5 | -1.1 | -0.7 | -1.4 | -0.9 | -2.1 | -1.1 | 0.5 | 1.1 | 1.7 | 2 |
| Cash Flow from Ops. ⓘ | -2.1 | 1.8 | 3.7 | 0.6 | 1.7 | 2.2 | 0.5 | -0.4 | -0.3 | 0.1 | - |
| Debt/CF from Ops. ⓘ | -9.1 | 9.5 | 3.3 | 19.4 | 6.7 | 5 | 24.2 | -25.5 | -3.8 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -8.1% | 2.8% | 46.4% | -0.4% | ||||
| Adj EPS ⓘ | NA | NA | NA | 62.4% | ||||
| BVPSⓘ | 2.4% | 14.9% | 49.3% | 9.3% | ||||
| Share Price | 14.1% | 37.4% | -10.8% | -24.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -11 | -9.4 | -5.9 | -14.5 | -10.4 | -30.4 | -21.5 | 5.6 | 6.6 | 8.6 | 7.6 |
| Op. Profit Mgn % ⓘ | -2 | -4.3 | 0.1 | 6 | 1.7 | 7 | -19.3 | 19.1 | 21.1 | 28.4 | 21.2 |
| Net Profit Mgn % ⓘ | -9.2 | -15.8 | -12.6 | -24.6 | -13.2 | -27 | -47.7 | 6.8 | 14.3 | 23.3 | 21 |
| Debt to Equity ⓘ | 1.5 | 1.5 | 1.1 | 1.4 | 1.4 | 1.9 | 2.4 | 0.8 | 0.1 | 0 | - |
| Working Cap Days ⓘ | 348 | 626 | 527 | 461 | 485 | 257 | 389 | 148 | 222 | 314 | 347 |
| Cash Conv. Cycle ⓘ | 209 | 442 | 355 | 178 | 122 | 61 | 88 | 19 | 49 | 37 | 321 |
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.4 | 9.4 |
| TTM Sales (₹ Cr.) | 7.9 | 185 |
| BVPS (₹.) ⓘ | 19.7 | 69.8 |
| Reserves (₹ Cr.) ⓘ | 11 | 69 |
| P/BV ⓘ | 4.98 | 1.41 |
| PE ⓘ | 68.27 | 10.40 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 81.00 / 193.50 |
| All Time Low / High (₹) | 8.40 / 193.50 |
| Market Cap (₹ Cr.) | 113 |
| Equity (₹ Cr.) | 11.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 39.3 |
| Mar'24 | YoY Gr. Rt. % | Jun'24 | YoY Gr. Rt. % | Sep'24 | YoY Gr. Rt. % | Dec'24 | YoY Gr. Rt. % | |
|---|---|---|---|---|---|---|---|---|
| Sales (₹ Cr.)ⓘ | 2,094 | -5.5 | 2,310 | -1.9 | 2,488 | 0.4 | 2,948 | 8.1 |
| Adj EPS (₹) ⓘ | 22.8 | 38.9 | 26.5 | 1.1 | 29 | 52.1 | 25.7 | 5.2 |
| Op. Profit Mgn % ⓘ | 12.45 | 192 bps | 14.08 | 2 bps | 10.64 | -2 bps | 11.29 | -64 bps |
| Net Profit Mgn % ⓘ | 11.33 | 204 bps | 12.47 | 36 bps | 13.03 | 454 bps | 9.78 | -14 bps |
| Pledged * | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 |
| Company Name | CMP(₹) | |||||||
|---|---|---|---|---|---|---|---|---|
| Alembic Pharma | 875.5 | -6 (-0.7%) | Small Cap | 6,229 | 30.8 | 9.6 | 28.7 | 3.5 |
| Laurus Labs | 625.4 | -21.8 (-3.4%) | Small Cap | 5,041 | 6.6 | 3.1 | 97.4 | 8.3 |
| Piramal Pharma | 216 | -3.9 (-1.8%) | Small Cap | 4,390 | 5.2 | 8.4 | 42.4 | 4.1 |
| Ajanta Pharma | 2,677.2 | -108.9 (-3.9%) | Small Cap | 4,209 | 71.9 | 19 | 38.8 | 8.9 |
| Gland Pharma | 1,451.4 | -14.2 (-1%) | Small Cap | 4,167 | 68.1 | 24.8 | 21.5 | 2.6 |
| Natco Pharma | 889.7 | -14 (-1.6%) | Small Cap | 3,999 | 104.1 | 34.5 | 8.7 | 2.2 |
| Granules India | 452.2 | -23.6 (-5%) | Small Cap | 3,755 | 13.3 | 11.7 | 35.8 | 3.5 |
| Emcure Pharma | 1,027.8 | -47.9 (-4.5%) | Small Cap | 3,498 | 8.5 | 4.4 | 126.7 | 7.1 |
| JB Chem & Pharma | 1,576.1 | -33.8 (-2.1%) | Small Cap | 3,299 | 40.4 | 16.1 | 39.9 | 7.6 |
| Wockhardt | 1,396.4 | -70.7 (-4.8%) | Small Cap | 2,798 | -11.8 | -15.3 | - | 5.4 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16 | 7 | 5 | 6 | 6 | 8 | 2 | 7 | 7 | 7 |
| Operating Expenses ⓘ | 16 | 8 | 5 | 7 | 6 | 7 | 3 | 6 | 6 | 5 |
| Manufacturing Costs | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
| Material Costs | 7 | 3 | 3 | 3 | 3 | 4 | 1 | 3 | 3 | 3 |
| Employee Cost | 3 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 |
| Other Costs ⓘ | 2 | 1 | 1 | 3 | 2 | 2 | 1 | 1 | 1 | 1 |
| Operating Profit ⓘ | 0 | 0 | 0 | -1 | 0 | 1 | 0 | 1 | 2 | 2 |
| Operating Profit Margin (%) | -2.0% | -5.6% | 0.0% | -19.1% | 1.7% | 7.0% | -19.3% | 19.1% | 21.0% | 28.4% |
| Other Income ⓘ | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Interest ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Depreciation ⓘ | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -2 | -1 | -1 | -2 | -1 | 0 | -1 | 1 | 2 | 2 |
| Tax ⓘ | -1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| Profit After Tax | -1 | -1 | -1 | -2 | -1 | -2 | -1 | 1 | 1 | 2 |
| PAT Margin (%) | -7.6% | -14.0% | -12.6% | -41.4% | -12.7% | -26.1% | -47.7% | 7.6% | 16.1% | 24.5% |
| Adjusted EPS (₹) | -1.4 | -1.2 | -0.8 | -2.8 | -1.0 | -2.4 | -1.3 | 0.6 | 1.1 | 1.6 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 13 | 12 | 11 | 9 | 8 | 6 | 5 | 11 | 19 | 21 |
| Share Capital ⓘ | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 |
| Reserves ⓘ | 4 | 3 | 2 | 0 | -1 | -3 | -4 | 1 | 8 | 10 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 17 | 15 | 10 | 12 | 11 | 11 | 11 | 8 | 0 | 0 |
| Long Term Debt | 15 | 13 | 7 | 8 | 8 | 3 | 2 | 1 | 0 | 0 |
| Short Term Debt | 2 | 2 | 3 | 4 | 2 | 8 | 9 | 7 | 0 | 0 |
| Trade Payables | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| Others Liabilities ⓘ | 1 | 1 | 0 | -2 | -1 | 0 | 0 | 2 | 1 | 0 |
| Total Liabilities ⓘ | 33 | 28 | 22 | 20 | 18 | 18 | 16 | 22 | 21 | 22 |
Fixed Assets | ||||||||||
| Gross Block | 17 | 16 | 7 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Accumulated Depreciation | 9 | 10 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Net Fixed Assetsⓘ | 7 | 7 | 6 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 11 | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Inventories | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Trade Receivables | 11 | 7 | 3 | 4 | 3 | 2 | 0 | 2 | 1 | 1 |
| Cash Equivalents | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 4 | 1 | 0 |
| Others Assetsⓘ | 2 | 2 | 1 | 5 | 5 | 5 | 5 | 5 | 7 | 10 |
| Total Assets ⓘ | 33 | 28 | 22 | 20 | 18 | 18 | 16 | 22 | 21 | 22 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -2 | 2 | 4 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
| PBT ⓘ | -2 | -1 | -1 | -2 | -1 | 0 | -1 | 1 | 2 | 2 |
| Adjustment ⓘ | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 1 | 0 | 0 |
| Changes in Working Capital ⓘ | -1 | 2 | 3 | -1 | 1 | 1 | 1 | -2 | -2 | -2 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Investments | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 2 | -2 | -4 | -1 | -2 | -2 | 0 | 5 | -3 | -1 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 2 | -2 | 0 | 0 | 0 | -6 | -1 | -1 | -1 | 0 |
| Interest Paid ⓘ | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -3 | 0 | -2 | 6 | 1 | 6 | -2 | -1 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | -1 | 1 | 0 | 4 | -3 | -1 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -9.07 | -8.38 | -5.9 | -24.44 | -10.04 | -29.37 | -21.49 | 6.92 | 7.95 | 9 |
| ROCE (%) | -1.1 | -1.14 | 1.42 | -5.43 | 2.85 | 5.04 | -2.57 | 7.8 | 8.85 | 12.45 |
| Asset Turnover Ratio | 0.48 | 0.24 | 0.21 | 0.27 | 0.34 | 0.43 | 0.14 | 0.37 | 0.35 | 0.35 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 | 0 |
| Working Capital Days | ||||||||||
| Receivable Days | 232 | 460 | 375 | 233 | 184 | 109 | 192 | 59 | 72 | 41 |
| Inventory Days | 59 | 44 | 20 | 21 | 23 | 14 | 56 | 35 | 33 | 36 |
| Payable Days | 171 | 161 | 73 | 136 | 124 | 81 | 273 | 123 | 83 | 69 |
Parnax Lab, earlier known as Krishnadeep Trade and Investments, incorporated in the year 1982, engages in investing and financial businesses in India. The company is based in Mumbai, India. In 2012 the company has changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd. "
In 2009, Krishna Deep Trade and Investments appointed Rasik Chaturvedi and Dilip Pimparkar as additional directors of the company with effect from February 16, 2009. Further, Rasik Chaturvedi and Dilip Pimparkar have also been inducted on the Audit Committee of the Company.
The registered office of the company is 136, Greet Western Building, Nagindas Master Road Extension, Fort Mumbai, Maharashtra-400001.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
100% Secure Process
Account Discovery
- OTP from CAMS
Account Linking for Stocks & MF
- One OTP per link Eg. NSDL, CDSL, CAMS, KFin etc.
One Click Upload for your Current Portfolio and Future Transactions!
Download APP
